IP Library Granted Patent US 10,441,610
Granted Patent B2
US 10,441,610 · App. 13/988,929 · Granted Oct 15, 2019

Protein delivery from stem cell microcarriers

Inventors: Barbara Dale Boyan (Richmond, VA); Zvi Schwartz (Richmond, VA); Christopher S. D. Lee (Atlanta, GA); Shirae Kerisha Leslie (Richmond, VA); Ramsey C. Kinney (Decatur, GA)
Assignee: Georgia Tech Research Corporation
A61K35/28A61K9/5036C12N5/0655C12N5/0667A61K2035/128C12N2500/25C12N2500/32C12N2500/34C12N2500/38C12N2501/15C12N2501/155C12N2501/39C12N2533/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,441,610
App. No.
13/988,929
Granted
Oct 15, 2019
Kind
B2
Abstract

Disclosed are methods and compositions of microbead carriers for delivery of cells and other biologically active substances to diseased or damaged tissue in a subject in need thereof.

Claims (11)

1. A composition for affecting chondrogenic gene expression when contacting a chondrocyte comprising injectable biodegradable polymeric hydrogel controlled-release microbeads, wherein the microbeads comprise mesenchymal stem cells and alginate, wherein alginate lyase is incorporated into the alginate, and wherein the expression, production, or secretion of an angiogenic factor or a hypertrophic factor or both by the mesenchymal stem cells is inhibited by contact with chondrogenic medium, or the expression, production, or secretion of a chondrogenic factor or an anti-hypertrophic factor or both by the mesenchymal stem cells is stimulated by contact with chondrogenic medium, and wherein the mesenchymal stem cells are obtainable by contact with a chondrogenic medium for 5 days.

2. The composition of claim 1 , wherein the microbeads are about 200 micrometers or less in diameter.

3. The composition of claim 1 , wherein the mesenchymal stem cells are adipose stem cells.

4. The composition of claim 3 , wherein the angiogenic factor is VEGF-A or FGF-2, or a combination of both.

5. The composition of claim 3 , wherein the hypertrophic factor is FGF-18.

6. The composition of claim 3 , wherein the chondrogenic factor is TGF-β1, TGF-β2, TGF-β3, IGF-1, or PTHrP, or a combination thereof.

7. The composition of claim 3 , wherein the anti-hypertrophic factor is Noggin.

8. The composition of claim 1 , wherein the microbeads are a renewable reservoir for the angiogenic factor, hypertrophic factor, chondrogenic factor, or anti-hypertrophic factor, or a combination thereof, which are expressed, produced, or secreted by the mesenchymal stem cells.

9. The composition of claim 8 , wherein the mesenchymal stem cells are adipose stem cells.

10. The composition of claim 1 , wherein the mesenchymal stem cells are are conditioned with chondrogenic medium before the stem cells are encapsulated in the microbeads.

11. The composition of claim 1 , wherein the mesenchymal stem cells are conditioned with chondrogenic medium after the stem cells are encapsulated in the microbeads.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 19, 2016
From: GEORGIA INSTITUTE OF TECHNOLOGY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 040069/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2013
From: BOYAN, BARBARA DALE; SCHWARTZ, ZVI; LEE, CHRISTOPHER S.D.; LESLIE, SHIRAE KERISHA; KINNEY, RAMSEY C.
To: GEORGIA TECH RESEARCH CORPORATION, A/C GEORGIA INSTITUTE OF TECHNOLOGY
Reel/Frame 031650/0673 →
Continuity (3)
Provisional Application 61416463 · Nov 23, 2010
Provisional Application 61426018 · Dec 22, 2010
Related Publication 20140370111A1 · Dec 18, 2014